microsoft word - jad_casamitjana_et al.docx mri-bas screen preclin alzheim  diseas prevent clinic trial adri casamitjanaa , paula petroneb , alan tucholkab , carl falconb , c , stavro skourasb , jos lui molinuevob , , e , vernica vilaplanaa* , juan domingo gispertb , c* , alzheim  diseas neuroimag initiativef author contribut equal .
author affili : depart signal theori communic , universitat politcnica de catalunya , barcelona , spain b barcelonaeta brain research center , pasqual maragal foundat .
barcelona , spain .
c centro de investigacin biomdica en red bioingenieria , biomaterial nanomedicina ( ciber- bbn ) .
spain alzheim  diseas cognit disord unit , hospit clnic , institut  investigacion biomdiqu august pi sunyer ( idibap ) , barcelona , spain .
e ciber fragilidad envejecimiento salud ( ciberf ) , madrid , spain .
f data use prepar articl obtain alzheim  diseas neuroimag initi ( adni ) databas ( adni.loni.usc.edu ) .
, investig within adni contribut design implement adni and/or provid data particip analysi write report .
complet list adni investig found : http : //adni.loni.usc.edu/wp-content/uploads/how_to_apply/adni_acknowledgement_list.pdf * correspond : dr. juan domingo gispert barcelonabeta brain research centr - pasqual maragal foundat c/ wellington 30 .
08005 barcelona , spain phone : +34 93 3160990 email : jdgispert @ barcelonabeta.org dr. veronica vilaplana depart signal theori communic , universitat politcnica de catalunya c/ jordi girona 1-3 , edifici d5 campus nord upc .
08034 barcelona , spain email : veronica.vilaplana @ upc.edu 2 abstract identif healthi individu harbor amyloid patholog constitut one import challeng secondari prevent clinic trial alzheim 's diseas .
consequ , noninvas cost-effici techniqu detect preclin ad constitut unmet need critic import .
manuscript , appli machin learn structur mri ( t1 dti ) 96 cognit normal subject identifi amyloid-posit one .
model train public adni data valid independ local cohort .
use subject classif simul clinic trial set , propos method abl save 60 % unnecessari csf/pet test reduc 47 % cost recruit use simul clinic trial set .
recruit strategi capit alreadi acquir mris reduc overal amount invas pet/csf test prevent trial , demonstr potenti valu tool ad screen .
protocol could foster develop secondari prevent strategi ad .
keyword : preclin alzheim  diseas , machin learn , clinic trial , secondari prevent , screen , amyloid patholog abbrevi : alzheim  diseas ( ad ) ; alzheim diseas neuroimag initi ( adni ) ; cerebrospin fluid ( csf ) ; diffusion-tensor imag ( dti ) ; diffusion-weight imag ( dti ) ; function magnet reson imag ( fmri ) ; grey matter volum ( gmv ) ; logist regress ( lr ) ; mild cognit impair due ad ( mci-ad ) ; normal control ( nc ) ; positron emiss tomographi ( pet ) ; precision-recal ( pr ) ; preclin stage ad ( pread ) ; receiver-oper curv ( roc ) ;  region interest ( roi ) ; structur connect matrix ( scm ) .
3 1 introduct alzheim  diseas ( ad ) neurodegen diseas character progress loss cognit abil specif neuropatholog alter , name plaqu beta-amyloid ( a ) tangl tau protein .
last decad seen paradigm shift ad perceiv biolog continuum rang way normal cognit dementia [ 1 ] .
new concept ad recogn presenc preclin stage ad ( pread ) preced symptomat phase mild cognit impair due ad ( mci-ad ) dementia due ad ( ad ) .
pread character cognit within normal rang abnorm amyloid biomark measur cerebrospin fluid ( csf ) positron emiss tomographi ( pet ) .
studi show amyloid biomark cognit healthi individu alter decad clinic diagnosi diseas , therefor , pread stage constitut window opportun prevent therapi [ 2 ] .
present , disease-modifi therapi fail show adequ efficaci clinic trial grow consensus trial focus earlier stage diseas , prompt treatment option irrevers neuron loss .
exampl , a4 ( anti-amyloid treatment asymptomat alzheim  diseas ) stand first secondari prevent trial aim prevent clinic symptom cognit healthi individu ad pathophysiolog .
howev , prevent trial pread stage face crucial ethic logist challeng .
among consider , slow buildup amyloid accumul requir long follow-up period , larg amount individu screen order achiev adequ statist power due small effect size .
critic success ad prevent strategi , effici , noninvas cost-effect method screen asymptomat at-risk subject prevent trial need develop .
mri proven instrument character impend dementia cognit declin due ad research clinic .
structur chang ad-vulner structur entorhin cortex , hippocampus tempor lobe constitut diagnost marker cognit impair [ 3,4 ] stand valid marker ad progress [ 4 ] .
moreov , mri modal ( magnet reson spectroscopi  [ 5 ] , diffusion-weight imag ( dwi )  [ 6 ] , diffusion-tensor imag ( dti ) [ 7,8 ] ) function magnet reson imag ( fmri ) [ 9 ] offer 4 complementari inform unveil specif ad alter differ stage ad spectrum .
hand , extent mri resolv structur connect chang preclin asymptomat stage ad still area open explor [ 10,11 ] .
machin learn field contribut batteri tool autom classif imag mri .
tool appli public avail data resourc dedic ad biomark discoveri .
exampl , alzheim diseas neuroimag initi ( adni ) [ 12 ] primari goal test whether serial mri , pet biolog marker , combin clinic neuropsycholog assess measur progress mci earli ad .
studi limit structur t1 data , recent effort also cover imag modal ( e.g .
asl [ 13 ] ) , knowledg , machin learn effort focus diagnost categori ( mci ad ) predict impend cognit declin .
recent review see [ 14 ] .
whether machin learn resolv signatur preclin ad remain investig .
furthermor , studi analyz practic util mri-bas screen recruit cognit normal volunt ad prevent trial .
work , propos mri-driven machin learn protocol identif cognit normal individu bear abnorm amyloid level implement clinic trial recruit .
propos protocol , use mri-bas machin learn model identifi subject like report abnorm amyloid biomark ( figur 1 ) .
replac gold standard measur , method gain knowledg alreadi acquir mris , minim amount pet csf test , exchang non-invas cost-effect mris .
assess util system pread screen base mri .
end , model train featur base brain morphometri structur connect use subset adni cohort .
, local cohort valid capac model prospect detect amyloid- posit individu .
final , determin benefit util classifi recruit subject secondari prevent trial .
taken whole , result show mri modal combin machin learn use practic cost-effect screen tool ad 5 prevent trial .
2 materi method 2.1 subject csf well t1 dti imag data 96 subject adni cohort [ 12 ] download .
subset adni select collect t1 dti imag acquir 3t scanner .
sampl , cognit normal subject classifi pread a42 csf concentr 192 pg/ml normal control ( nc ) els .
threshold a posit ( a+ ) select optim discrimin control ad patient adni-independ autopsy-bas ad csf sampl analys multiplex xmap lumnex platform [ shaw et al .
ann neurol .
2009 apr ; 65 ( 4 ) : 403413 ] , mci ad classif criteria appli adni project report elsewher [ 17 ] refin exclus consid a+ individu .
classif criteria result 28 normal control ( nc ) , 16 pread , 23 mci due ad [ mci ] , 29 ad .
equival csf , t1 dti imag data also acquir single-sit cohort ad unit hospit clinic barcelona ( hcb ) includ 87 subject ( 40 nc , 12 pre-ad , 21 mci due ad [ mci ] , 14 ad ) .
subject classifi pread cognit normal a+ , defin accord recommend refer valu innotest elisa ( csf a42 < 500 pg/ml ) [ 10,15,16 ] .
criteria mci ad previous report [ 10 ] , note , includ a+ patient .
local ethic committe approv studi particip gave written inform consent .
2.2 imag acquisit process hcb particip underw mri 3t siemen triotim scanner provid 3d t1- weight imag follow paramet : repetit time ( tr ) = 2300 ms , echo time ( te ) = 2.98 ms , invers time ( ti ) = 900 ms , flip angl = 9 , voxel resolut 111 mm3 240 sagitt slice ; two diffusion-weight sequenc : tr = 7600 ms , te = 89 ms , flip angl = 90 , 30 non-collinear direct ( b = 1000 s/mm2 ) 1 non-gradi volum ( b = 0 ) , voxel size 2.052.052 mm3 60 6 axial slice .
adni particip scan 3t ge mri model , 13 differ site , compris 3d t1-weight imag : tr = 7.256 ms , te = 2.988 ms , ti = 400 ms , flip angl = 11 , voxel resolut 1.021.021.2 mm3 196 sagitt slice ; diffusion-weight sequenc : tr = 13000 ms , te = 69.1 ms , flip angl = 90 , 41 non-collinear direct ( b = 1000 s/mm2 ) 5 non-gradi imag , voxel resolut 1.36721.36722.7 mm3 59 axial slice .
t1-weight imag segment statist parametr map ( spm ) vbm8 toolbox [ 18 ] obtain csf , gray matter ( gm ) , white matter ( wm ) probabilist map .
, binari gm mask form voxel whose probabl belong gm bigger probabl belong tissu .
aal atlas [ 19 ] montreal neurolog institut ( mni ) standard space warp subject  t1 nativ space mean ant ( upenn , uva uiowa , usa ; http : //stnava.github.io/ants/ ) use dartel templat obtain segment step .
aal map reslic t1 resolut use nearest neighbour interpol intersect gm mask .
volum aal region comput everi subject normal total intracrani volum , calcul sum csf , wm gm mask .
structur connect matric ( scm ) also comput .
end , aal region superimpos dti data use similar protocol one describ .
tractographi , creat seed mask insensit grey matter volum chang , interfac grey white matter dilat one voxel .
, probabilist tractographi perform pair aal region use fsl 's probtrackx  [ 20 ] ( see detail [ 16 ] ) .
2.3 overview machine-learn method core machin learn pipelin train use adni cohort dataset test local dataset hcb ( figur 2 ) .
perform overal system valid use csf/pet biomark gold-standard .
featur extract select .
featur select techniqu use retriev reduc set inform featur high dimension medic imag .
t1-weight imag , 7 extract 90-dimension vector correspond grey matter volum ( gmv ) 90 region interest ( roi ) describ aal atlas .
dti imag , extract 90x90 structur connect matrix ( scm ) atlas roi ( scm ) .
upper triangular determin 4005- featur vector .
differ acquisit protocol across medic center introduc bias reflect consider variabl distribut imag featur vector .
thus , imag featur normal use z-score comput independ cohort make data compar ensur standard featur weight .
differ filter featur select method compar perform .
focus balanc relev redund subset featur three method evalu purpos : f-test , mrmr-fcd mrmr-fcq [ 21 ] .
first two provid optim perform select t1 dti imag featur respect use throughout studi .
discard use wrapper embed featur select method sinc sensibl small sampl size result high general error indic sever overfit train set .
classif .
cognit normal individu ( nc pread ) two cohort use train test classifi predict dichotom a status ( either posit negat ) .
adni cohort use train classifi hcb data test .
addit , two differ classifi built , one base t1 data alon , anoth one , base combin t1 dwi data .
differ classif scheme test , includ logist regress ( lr ) , support vector machin ( svm ) linear gaussian kernel , random forest k-nearest neighbour , linear method ( logist regress linear-svm ) succes , give similar result practic .
final , due slight better perform easier interpret model , binari lr classifi use l2 regular penalti term  , optim cross-valid strategi 8 adni cohort .
lr classifi output score subject interpret probabl a+ a- , valid csf biomark readout .
optim model test perform term save cost clinic trial recruit .
end , precis ( fraction posit predict correct classifi ) ) , recal ( also known sensit , i.e .
fraction posit instanc correct classifi ) specif ( fraction negat instanc correct classifi ) calcul use dichotom csf a gold standard .
precision-recal ( pr ) receiver-oper curv ( roc ) also comput evalu method perform .
see formula appendix .
target normal popul mean age 65 , preval amyloid patholog estim 20 % [ 2 ] .
employ bootstrap approach simul requir diseas preval iter repeat classif protocol , yield differ split test set run .
secondari analysi sake compar previous report ad/mci classifi ,  optim diagnost  classifi deriv ident pipelin use nc , mci ad subject two cohort discrimin nc-mci nc-ad ( detail see appendix b ) .
final , also assess perform classifi optim discrimin pread nc classifi nc vs. diagnost categori ( mci ad ) .
save .
save clinic trial recruit calcul percentag differ resourc standard recruit protocol propos protocol mri-bas classifi ( figur 1 ) obtain desir number pread subject clinic studi .
save assess term econom cost ( equat [ 1 ] ) particip burden ( equat [ 2 ] ) i.e .
amount unnecessari pet/csf test spare mri-screen .
eq .
[ 1 ] eq .
[ 2 ] term precis ( p ) , recal ( r ) , cost mri csf test estim cmri = 700 , 9 cpet = 3000 .
cavg repres averag cost among screen test may includ addit cost ( e.g .
neuropsycholog cognit test ) .
simplic , perform calcul sole use imag cost .
general formul save structur formula provid appendic c & d. classifi threshold feature-extract method optim enhanc save eq .
[ 1 ] visual precision-recal curv .
3 result first report standard protocol make data action across train test cohort ( section 3.1 ) .
, evalu perform classifi base gmv t1-weight imag ( section 3.2 ) extend classifi base combin t1 dti featur ( section 3.3 ) .
demograph characterist studi sampl shown tabl 1 .
3.1 data normal follow normal raw imag featur train cohort ( adni ) test cohort ( hcb ) , result distribut z-score featur confirm match distribut kolmogorov-smirnov ( ks ) test ( p < = 0.05 ) ( figur 3 ) .
3.2 classif pread subject use t1-weight imag f-test select provid discrimin featur classif nc vs pread base adni data ( figur 4 , appendix ) .
classif algorithm provid rank weight featur ( figur 4 ) base relev .
maxim area roc curv ( auc ) maxim clinic recruit save achiev 20 t1 featur ( tabl 2 ) .
3.3 classif pread subject use multimod featur vector multimod classif perform combin imag featur t1 dti .
z-score transform featur concaten modal yield 4095-dimension featur vector .
optim pr threshold yield highest save high depend number featur use 10 classifi ( tabl 3 , figur 5 ) .
featur select mrm-fcd [ 21 ]  method result 45- dimension featur vector ( featur list appendix ) .
notabl , 2 45 inform featur t1 featur ( featur 18 : olfactori ( l ) , featur 23 : pallidum ) , 43 dti feature-pair .
result suggest dti featur may inform t1 featur identifi preclin subject .
figur 5 show dti-connect region , given weight sum dti-featur pair reflect relev identif pread .
exampl , pallidum highlight roi multipl connect well gmv featur .
remark , almost perform ( auc ) cost save obtain t1 multimod classifi precis higher ( p = 0.85 ) multimod model t1 case ( p = 0.54 ) result larger save regard particip burden ( 76.5 % ) .
descript associ csf a42 level tractographi fall beyond interest work describ elsewher [ 16 ] .
3.4 classif nc vs mci/ad subject t1-on classifi optim discrimin nc mci/ad patient yield auc compar state-of-the-art method ( auc > 0.89 ) .
addit dti data margin improv classif perform ( auc > 0.91 ) .
, metric achiev hcb cohort train classifi adni dataset .
hand , classifi optim discrimin nc pread subject yield auc < 0.20 discrimin among nc diagnost categori ( i.e .
mci , ad ) .
detail see appendix c. 4 discuss work investig autom screen pread individu use machin learn method featur deriv structur mri .
present potenti integr technolog screen tool recruit subject secondari prevent trial present framework quantifi benefit approach econom particip burden term .
noteworthi , 11 propos replac gold standard pet/csf test , provid predict amyloid posit order avoid unnecessari pet/csf test , thus , reduc particip burden econom cost .
valid across cohort .
util public mri csf data avail adni featur select model train .
independ hcb cohort serv model test , simul real trial recruit scenario .
data normal scheme enabl valid overcom differ data acquisit protocol scanner institut .
thus , relev model general popul sampl , differ age educ rang .
note , perform algorithm stabl revers train test dataset .
therefor , forese perform pread classif hold prospect appli independ cohort practic util pread screen purpos .
featur select .
design , data-driven approach agnost previous report anatom chang due ad .
allow us valid select featur given role preclin prodrom stage ad accord literatur .
expect , featur found inform pread classif relat establish ad signatur .
case t1 , characterist ad affect region includ atlas roi hippocampus amygdala , tempor pariet area well cingulum , thalamus , rectus fusiform giri ( figur 4 ) .
region olfactori bulb pertain well document alter olfactori system pathogenesi ad dementia [ 22 ] .
region show high discrimin power caudat , found alter cognit normal individu high genet risk develop ad [ 23,24 ] .
final , role region globus pallidus clear pread ( figur 5 ) .
one explan would atlas roi includ nucleus basali meynert , adjac region explicit identifi aal parcel .
previous voxelwis analysi hcb cohort , nucleus basali show alter pread [ 15 ] , moreov , region consist report degener earli ad stage [ 25 ] .
interest , featur classifi nc pread yield auc < 0.2 discrimin among nc diagnost categori ( i.e .
mci , ad ) .
auc signific depart 0.5 classifi de facto .
howev , well 0.5 12 suggest featur character pread nc appear opposit direct featur classifi nc vs ad .
interpret reinforc fact classif model built use ident pipelin train specif recogn diagnost categori perform accord report literatur ( auc=0.95 20 t1 featur , p=1.0 , r=0.76 ) , base main hippocamp tempor lobe volum ( appendix b ) .
futur work improv identif discrimin brain region use voxelwis approach fulli character preclin ad signatur use mri identifi overlap establish ad signatur  [ 24 ] .
overal , result show featur select priorit dti featur t1 featur multimod imag vector .
thus , dti feature-pair may robust t1 featur , compens lower imag qualiti ( resolut , nois , blur ) artifact given surrog measur brain anatom connect dti .
also , dti convey complementari inform white matter connect .
data rais question whether chang connect may evid earli ad volumetr chang [ 16 ] .
nevertheless , relev dti t1 featur observ studi confirm dataset .
despit similar perform , multimod model precis t1-base model , translat less fals posit therefor less unnecessari pet/csf test exchang mri scan given low recal model .
rang applic pread preval .
proof-of-concept studi , mri-bas classifi threshold optim maxim cost save .
model tune applic minim particip burden ( equat 2 ) .
practic util mri-bas screen protocol high depend preval pread subject , turn , intim relat age rang age distribut clinic studi .
lower diseas preval , save reli higher classifi precis make mri-bas screen layer worthwhil ( equat 1 ) .
propos recruit protocol effici 13 younger cohort also best suit secondari intervent trial .
precis vs. recal .
higher classifi precis reduc number unnecessari pet/csf acquisit ( less false-posit ) .
higher classifi recal reduc size initi particip pool mri imag need acquir limit amount fals negat miss classif .
ensur cognit healthi particip pool also incur associ cost ( e.g .
addit cognitive/clin test ) scale number particip .
true mri-bas screen reli recruit larger initi cognit healthi particip pool therefor mri scan cognit test , estim propos protocol still effici term save econom particip burden ( see appendix c detail complex save structur ) .
exampl applic .
standard clinic trial recruit protocol , preval pread 20 % , 1500 individu need undergo csf/pet test order identifi 300 a+ subject .
first , preliminari mri scan acquir exclud particip display incident find neuroradiolog exclus criteria .
instead , modest mri-bas classifi ( 0.54 precision/0.84 recal ) , requir 1807 mri imag predict ident pool 300 a posit individu .
imag , 555 predict posit sent csf/pet valid , 300 result true posit 255 fals posit .
second protocol would spare 945 pet/csf test , exchang addit 307 mris requir compens fals negat miss classifi .
econom term , save provid mri-screen layer prevent 60 % unnecessari pet/csf scan save 47 % cost compar standard protocol reli gold standard csf/pet measur .
comparison approach detect a .
present , blood-bas approach detect a+ activ pursu ( nakamura et al .
natur volum 554 , page 249254 ( 08 februari 2018 ) doi:10.1038/nature25456 ; ovod et al .
alzheim dement .
2017 aug ; 13 ( 8 ) :841-849 ; naber et al .
embo mol med .
2018 may ; 10 ( 5 ) .
method show high concord ( aucs~0.80-0.90 ) plasma a speci pet imag .
unlik pread group includ 14 cognit normal subject , perform method estimati includ mci and/or ad patient might favour .
nevertheless , work demonstr link cerebr peripher a alter , valid autom , repres major resourc screen general popul implement secondari ad prevent strategi .
hand , mri-bas approach might particular use context research studi csf pet imag envisag , case mri scan typic prescrib safeti reason .
limit .
main limit studi small sampl size studi group .
due limit avail t1 dti data individu two cohort .
nevertheless , previous report standard evalu algorithm computed-aid diagnosi dementia base structur mri recommend use small train set ( n~30 ) mimic clinic set limit data avail avoid overtrain issu [ bron et al .
neuroimag .
2015 may 1 ; 111:562-79 ] .
hand , maxim generaliz perform evalu , priorit appli algorithm independ dataset differ demograph scan paramet .
base rational , prioritis test algorithm independ cohort total sampl size .
nevertheless , futur studi focus valid similar approach larger test set better account sampl demograph confound .
end , given result report , t1 data might sole achiev similar level classif accuraci .
addit , small sampl size limit complex machin learn scheme could implement robust .
futur studi bigger sampl size also allow investig potenti improv classif perform complex classifi scheme .
nevertheless , consid report promis proof-of-concept , even simpl logist regress model , robust perform achiev across two independ dataset distinct demograph characterist , potenti lead signific save gold-standard procedur .
anoth limit experiment approach threshold a+ might complet equival across two cohort .
respect csf a cut-off independ valid 15 yield optim discrimin nc ad patient respect analyt platform ( innotest elisa hcb xmap-luminex adni ) .
absolut valu definit compar , correl shown high ( r > 0.75 [ irwin et al arch neurol .
2012 aug ; 69 ( 8 ) : 10181025 ; wang et al .
j alzheim dis .
2012 ; 31 ( 2 ) : 439445 , fagan et al .
arch neurol .
2011 sep ; 68 ( 9 ) : 11371144 . ] ) .
nevertheless , accord publish convers equat , respect threshold within interlaboratori reproduc analyt platform fall rage 15-30 % ( % cv ) [ kang clin chem .
2013 jun ; 59 ( 6 ) : 903916 . ] .
base rational , prefer use publish valid cut-off compar previous report respect dataset .
similar limit may aris equat posit base csf pet data unless cut-off defin modal , like hansson et al alzheim dement .
2018 mar 1. pii : s1552-5260 ( 18 ) 30029-3. doi : 10.1016/j.jalz.2018.01.010 .
futur develop .
studi restrict limit subject sampl therefor model recogn limit aspect pread signatur .
expect enhanc perform use larger train set .
adopt atlas roi-bas approach use aal atlas implement rather coars parcel ; futur work explor addit fine-grain atlas even explor voxel-bas multivari approach .
despit modest perform , model could still appli prospect classif independ cohort .
follow-up effort involv applic workflow larger imag dataset one acquir within alfa project [ 25 ] .
anoth line improv predict actual csf a42 level order dichotom result later stage order accommod optim a42 threshold differ applic .
5 conclus proof-of-concept studi , establish machin learn detect amyloid patholog cognit normal popul use t1 dti mri .
method use prospect pread screen subject futur cohort , follow appropri data standard .
approach lead signific reduct particip burden econom cost .
propos applic meant replac gold-standard techniqu determin amyloid patholog .
16 inde , benefit method reli ad valu mri imag alreadi acquir , prior pet scan secondari prevent trial .
near futur , ought explor biomark ( p-tau , t-tau ) risk factor ( apoe4 , app ) relationship multimod imag featur identif preclin ad .
taken togeth , mri-bas pread detect make valuabl tool secondari prevent trial valid prospect multicent clinic trial .
17 6 acknowledg pp thank grgori operto raffael cacciagglia insight comment .
work partial support project biggraph-tec2013-43935- r malegra tec2016-75976- r financ spanish ministerio de economa competitividad european region develop fund ( erdf ) .
ac support spanish  ministerio de educacin , cultura deport  fpu research fellowship .
juan gispert hold  ramn cajal  fellowship ( ryc-2013 13054 ) .
data collect share project fund alzheim 's diseas neuroimag initi ( adni ) ( nation institut health grant u01 ag024904 ) dod adni ( depart defens award number w81xwh-12-2-0012 ) .
adni fund nation institut age , nation institut biomed imag bioengin , generous contribut follow : abbvi , alzheim  associ ; alzheim  drug discoveri foundat ; araclon biotech ; bioclinica , inc. ; biogen ; bristol- myer squibb compani ; cerespir , inc. ; cogstat ; eisai inc. ; elan pharmaceut , inc. ; eli lilli compani ; euroimmun ; f. hoffmann-la roch ltd affili compani genentech , inc. ; fujirebio ; ge healthcar ; ixico ltd. ; janssen alzheim immunotherapi research & develop , llc .
; johnson & johnson pharmaceut research & develop llc .
; lumos ; lundbeck ; merck & co. , inc. ; meso scale diagnost , llc .
; neurorx research ; neurotrack technolog ; novarti pharmaceut corpor ; pfizer inc. ; piram imag ; servier ; takeda pharmaceut compani ; transit therapeut .
canadian institut health research provid fund support adni clinic site canada .
privat sector contribut facilit foundat nation institut health ( www.fnih.org ) .
grante organ northern california institut research educ , studi coordin alzheim  therapeut research institut univers southern california .
adni data dissemin laboratori neuroimag univers 18 southern california .
7 disclosur statement author conflict interest report 8 refer [ 1 ] sperl ra , aisen ps , beckett la , bennett da , craft , fagan , et al .
toward defin preclin stage alzheim  diseas : recommend nation institut aging-alzheim  associ workgroup diagnost guidelin alzheim  diseas .
alzheim  dement 2011 ; 7:28092 .
doi:10.1016/j.jalz.2011.03.003 .
[ 2 ] jansen wj , ossenkoppel r , knol dl , tijm bm , schelten p , verhey frj , et al .
preval cerebr amyloid patholog person without dementia : meta- analysi .
jama 2015 ; 313:192438 .
doi:10.1001/jama.2015.4668 .
[ 3 ] frisoni gb , fox nc , jack cr , schelten p , thompson pm , thompson pm .
clinic use structur mri alzheim diseas .
nat rev neurol 2010 ; 6:6777 .
doi:10.1038/nrneurol.2009.215 .
[ 4 ] racin , adluru n , alexand al , christian bt , okonkwo oc , oh j , et al .
associ white matter microstructur amyloid burden preclin alzheim  diseas : multimod imag investig .
neuroimag clin 2014 ; 4:60414 .
doi:10.1016/j.nicl.2014.02.001 .
[ 5 ] graff-radford j , kantarci k. magnet reson spectroscopi alzheim  diseas .
neuropsychiatr dis treat 2013 ; 9:68796 .
doi:10.2147/ndt.s35440 .
[ 6 ] clerx l , visser pj , verhey f , aalten p. new mri marker alzheim  diseas : meta-analysi diffus tensor imag comparison medial tempor lobe measur .
j alzheim dis 2012 ; 29:40529 .
doi:10.3233/jad-2011-110797 .
[ 7 ] prescott jw , guidon , doraiswami pm , roy choudhuri k , liu c , petrella jr , et al .
alzheim structur connectom : chang cortic network topolog increas amyloid plaqu burden .
radiolog 2014 ; 273:17584 .
doi:10.1148/radiol.14132593 .
[ 8 ] nir tm , jahanshad n , villalon-reina je , toga aw , jack cr , weiner mw , et al .
effect region dti measur distinguish alzheim  diseas , mci , normal age .
neuroimag clin 2013 ; 3:18095 .
doi:10.1016/j.nicl.2013.07.006 .
[ 9 ] filippi , agosta f. structur function network connect breakdown alzheim  diseas studi magnet reson imag techniqu .
j alzheim dis 2011 ; 24:45574 .
doi:10.3233/jad-2011-101854 .
[ 10 ] molinuevo jl , ripoll p , sim , llad , oliv j , balasa , et al .
white matter chang preclin alzheim  diseas : magnet reson imaging-diffus tensor imag studi cognit normal older peopl posit amyloid  19 protein 42 level .
neurobiol age 2014 ; 35:267180 .
doi:10.1016/j.neurobiolaging.2014.05.027 .
[ 11 ] chtelat g , la joie r , villain n , perrotin , de la sayett v , eustach f , et al .
amyloid imag cognit normal individu , at-risk popul preclin alzheim  diseas .
neuroimag clin 2013 ; 2:35665 .
doi:10.1016/j.nicl.2013.02.006 .
[ 12 ] adni | alzheim  diseas neuroimag initi n.d. http : //adni.loni.usc.edu/ ( access juli 13 , 2017 ) .
[ 13 ] collij le , heeman f , kuijer jpa , ossenkoppel r , benedictus mr , mller c , et al .
applic machin learn arteri spin label mild cognit impair alzheim diseas .
radiolog 2016 ; 281:86575 .
doi:10.1148/radiol.2016152703 .
[ 14 ] falahati f , westman e , simmon a. multivari data analysi machin learn alzheim  diseas focus structur magnet reson imag .
j alzheim dis 2014 ; 41:685708 .
doi:10.3233/jad-131928 .
[ 15 ] gispert jd , rami l , snchez-benavid g , falcon c , tucholka , roja , et al .
nonlinear cerebr atrophi pattern across alzheim  diseas continuum : impact apoe4 genotyp .
neurobiol age 2015 ; 36:2687701 .
doi:10.1016/j.neurobiolaging.2015.06.027 .
[ 16 ] tucholka , grau-rivera , falcon c , rami l , snchez-vall r , llad , gispert jd , molinuevo jl , alzheim  diseas neuroimag initi .
structur connect alter along ad continuum : reproduc across two independ sampl correl csf a tau .
j alzheim dis .
2018 ; 61 ( 4 ) :1575-1587. doi : 10.3233/jad-170553 .
[ 17 ] jack cr , albert ms , knopman ds , mckhann gm , sperl ra , carrillo mc , et al .
introduct recommend nation institut aging-alzheim  associ workgroup diagnost guidelin alzheim  diseas .
alzheim dement 2011 ; 7:25762 .
doi:10.1016/j.jalz.2011.03.004 .
[ 18 ] spm - statist parametr map n.d. http : //www.fil.ion.ucl.ac.uk/spm/ ( access juli 13 , 2017 ) .
[ 19 ] tzourio-mazoy n , landeau b , papathanassiou , crivello f , etard , delcroix n , et al .
autom anatom label activ spm use macroscop anatom parcel mni mri single-subject brain .
neuroimag 2002 ; 15:27389 .
doi:10.1006/nimg.2001.0978 .
[ 20 ] jenkinson , beckmann cf , behren tej , woolrich mw , smith sm .
fsl .
neuroimag 2012 ; 62:78290 .
doi:10.1016/j.neuroimage.2011.09.015 .
[ 21 ] hanchuan peng h , fuhui long f , ding c. featur select base mutual inform criteria max-depend , max-relev , min-redund .
ieee tran pattern anal mach intel 2005 ; 27:122638 .
doi:10.1109/tpami.2005.159 .
[ 22 ] ten kate , sanz-arigita ej , tijm bm , wink , clerigu , garcia-sebastian , et al .
impact apoe-4 famili histori dementia grey matter atrophi cognit healthi middle-ag adult .
neurobiol age 2016 ; 38:1420 .
doi:10.1016/j.neurobiolaging.2015.10.018 .
20 [ 23 ] groth , heinsen h , teipel sj .
atrophi cholinerg basal forebrain adult age rang earli stage alzheim  diseas .
biol psychiatri 2012 ; 71:80513 .
doi:10.1016/j.biopsych.2011.06.019 .
[ 24 ] dickerson bc , bakkour , salat dh , feczko e , pacheco j , greve dn , et al .
cortic signatur alzheim  diseas : region specif cortic thin relat symptom sever mild mild ad dementia detect asymptomat amyloid-posit individu .
cereb cortex 2009 ; 19:497510 .
doi:10.1093/cercor/bhn113 .
[ 25 ] molinuevo jl , gramunt n , gispert jd , fauria k , estel , minguillon c , et al .
alfa project : research platform identifi earli pathophysiolog featur alzheim  diseas .
alzheim  dement transl res clin interv 2016 ; 2:8292 .
doi:10.1016/j.trci.2016.02.003 .
21 tabl 1 - demograph biomark , hcb adni separ , hcb adni merg togeth .
* signific differ vs. control group ( p < 0.05 ) .
 signific differ vs. preclin group ( p < 0.05 ) .
 signific differ vs. group hcb popul ( p < 0.05 ) .
group : nc- normal control , pre- preclin , mci- mild cognit impair due ad , ad- alzheim  diseas patient .
hcb adni nc pre mci ad nc pre mci ad n 40 12 21 14 28 16 23 29 n total 87 96 women/men 26/14 7/5 10/11 8/6 15/13 10/6 7/16 11/18 w=51 , m=36 w=43 , m=53 mean age 62.1 72.7* 70* 65.9 71.8 75.8* 72.4 74.2 sd 8.5 6 7.5 9 5.1 4.6 8 7.8 mean schol .
11.9 10.6 11 8.6* 17.2 16.2 16.1 15.2* sd 4.4 4 4.3 4.2 2.6 2.1 2.8 2.8 apoe4 car .
9 4 10 8 7 8 21 20 non-carri 31 8 10 6 21 8 2 9 mean a 760.8 375.8 339.1 310.7 239 148.5 135.7 130 sd 160.3 80.1 71.9 83.9 25.7 24.1 20.7 23.1 mean p-tau 56.6 76.6 112.2 105.7 31.2 51.7 52.9 66.6 sd 27.7 47.8 43.7 43 12.2 32.9 18.7 43 22 nc vs pread featur auc precis recal save % ( cost ) save % ( csf/pet ) 10 0.65 0.48 0.75 40.9 58.3 20 0.76 0.54 0.83 47.1 62.9 30 0.70 0.37 0.83 33.4 45.9 40 0.65 0.42 0.66 32.7 52.3 50 0.61 0.36 0.58 22.3 44.4 tabl 2 : perform pread classif model accord number featur select ( 10 , 20 , 30 , 40 , 50 ) .
classif nc vs pread , optim perform ( auc = 0.76 ) achiev 20 featur optim p-r threshold produc highest save highlight .
23 nc vs pread featur auc precis recal save % ( cost ) save % ( csf/pet ) 10 0.70 0.41 0.68 32.6 51.2 20 0.65 0.60 0.59 40.9 66.6 30 0.70 0.54 0.59 37.9 62.9 40 0.69 0.83 0.51 43.3 75.9 45 0.69 0.85 0.60 49.3 76.5 50 0.70 0.66 0.60 43.8 69.7 tabl 3 : perform classif accord number featur select ( 10 , 20 , 30 , 40 , 45 , 50 ) .
optim perform ( auc = 0.69 ) provid 45 featur .
optim pr threshold produc highest save list ( savingscost = 49 % , savingscsf/pet = 76.5 % ) .
24 figur 1 : outlin clinic recruit protocol subject pread pathophysiolog .
( ) standard recruit protocol use clinic trial .
( b ) propos protocol mri-bas machin learn .
standard protocol , cognit healthi particip undergo mri scan identifi radiolog exclus criteria ( e.g .
cerebrovascular diseas ) .
cognit healthi subject brain injuri particip pet/csf test , fraction a posit determin diseas preval .
propos protocol add exclus layer autom mri-bas classif predict subset pread subject later subject pet/csf acquisit .
case , target cohort defin true posit rate ( tp % ) classif algorithm .
initi particip pool need larger propos protocol due classifi fals negat may exclud .
25 figur 2 : core model train valid autom mri-bas classif a-posit ( a+ ) subject use logist regress .
adni dataset use model train .
featur extract gmvs roi follow featur select dimension reduct .
paramet model optim iter base train data maxim perform measur term area receiver-oper characterist curv ( roc ) .
final model test hbc dataset predict a+ subject valid use csf biomark ground truth .
model predict perform assess term area roc overal save produc altern recruit scenario includ mri-bas classif .
26 figur 3 .
exampl distribut t1 featur three gmv roi ( ) ( b ) z- score normal .
adni hbc cohort distribut shown red blue respect .
27 figur 4 : ( ) roi featur select best perform method ( f-test , 20 featur ) .
( b ) rank list inform featur accord weight provid lr decis function ( adni cohort ) .
( c ) roc analysi method perform 10 , 20 , 30 top rank featur base valid cohort ( hcb ) .
( ) savingscost function precision-recal calcul base optim number featur ( n = 20 ) appli hcb cohort .
color scale dash contour line indic save .
particular , contour line savings= 0.001 demark boundari area precision-recal curv save > 0 .
optim pr threshold provid highest save ( p = 0.54 , r = 0.83 , save = 47 % ) .
horizont dot line p=0.2 denot save random classifi , note precis valu equal preval pread popul .
28 figur 5 : ( ) exampl roi dti connect pallidum feature-pair multimod vector machin learn .
( b ) rank list connect roi accord weight sum featur scm matrix base train set adni .
weight provid lr decis function .
( c ) roc analysi method perform 30 , 44 , 55 top rank featur multimod t1+dti featur vector base valid dataset hcb .
( ) savingscost function precision-recal calcul base optim number featur ( n = 45 ) calcul valid dataset hcb .
color scale dash contour line indic save .
contour line savings= 0.001 demark boundari meaning area precision-recal curv savings= 0 .
optim p vs r pair provid highest save ( p = 0.85 , r = 0.60 , savingscost = 49 % ) .
horizont dot line p=0.2 denot save random classifi .
